The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML).
Rudiger Hehlmann
No relevant relationships to disclose
Benjamin Hanfstein
No relevant relationships to disclose
Martin C Müller
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Philipp Erben
Research Funding - Novartis
Michael Lauseker
No relevant relationships to disclose
Alice Fabarius
No relevant relationships to disclose
Susanne Schnittger
Employment or Leadership Position - MLL, Münchner Leukämie Labor
Claudia Haferlach
Employment or Leadership Position - MLL, Münchner Leukämie Labor
Gudrun Goehring
No relevant relationships to disclose
Stefan W. Krause
No relevant relationships to disclose
Jolanta Dengler
No relevant relationships to disclose
Christiane Falge
No relevant relationships to disclose
Andreas Neubauer
No relevant relationships to disclose
Frank Stegelmann
No relevant relationships to disclose
Michael Pfreundschuh
No relevant relationships to disclose
Karsten Spiekermann
No relevant relationships to disclose
Gabriela M Baerlocher
No relevant relationships to disclose
Joerg Hasford
No relevant relationships to disclose
Susanne Saussele
No relevant relationships to disclose
Andreas Hochhaus
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis